/PRNewswire/ According to a new market research report titled, "HLA Typing Market by Product (Instruments, Software), Technology (Molecular [PCR, Sequencing.
REDDING, Calif., Nov. 1, 2022 /PRNewswire/ According to a new market research report titled, "HLA Typing Market by Product (Instruments, Software), Technology (Molecular [PCR, Sequencing
H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx NeuroSciences NV today announced the acquisition of ADx NeuroSciences by Fujirebio for 40 million euros. Pending
Fujirebio Diagnostics Lumipulse® G β-Amyloid Ratio (1-42/1-40) In Vitro Diagnostic Test Receives Marketing Authorization for the Assessment of Alzheimer's Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Fujirebio enters the field of fully automated blood-based Alzheimer’s disease biomarker testing with the release of the Lumipulse® G pTau 181 Plasma assay for Research Use Only - read this article along with other careers information, tips and advice on BioSpace